CLDF ACE app analytics for 18 marzo

CLDF ACE
- Focus Medical Communications, LLC
- App Store di Apple
- Gratis
- Settore Medico
The CLDF ACE app is designed for health care professionals interested in liver disease. The content of this app is for educational purposes only and designed to provide useful information for providers and stakeholders to better understand how to effectively manage various liver conditions based on expert opinions and liver related clinical research and published articles.
CLDF ACE is your free, customized, open educational exchange for expert opinions, conference coverage, emerging data, management algorithms, AI, and other unique forms of digital education.
Chronic Liver Disease Foundation Application for Clinical Exchange (CLDF ACE) is an educational based platform that provides tailored medical education, tools, resources, and information for Health Care Providers in the field of Liver and Gastroenterology Diseases. CLDF ACE is an educational exchange application that ensures all users opt in and must agree to its terms and conditions before using the CLDF application.
This application is for education only and is not intended for medical advice or consultation.

Classifica degli store
La classifica del store si basa su diversi parametri stabiliti da Google e Apple.
Tutte le categorie in
Germania--
Settore Medico in
Germania--
Crea un account per visualizzare il numero mensile medio di downloadContattaci
CLDF ACEStatistiche di ranking nel tempo
Classifica di Utilizzo di Similarweb e Classifica App Store di Apple per CLDF ACE
Rank
Nessun dato disponibile
CLDF ACE Classifica per paese
Paesi in cui CLDF ACE ha la posizione più alta nelle sue categorie principali
Nessun dato da visualizzare
Principali concorrenti e app alternative
App con un'alta probabilità di essere utilizzate dagli stessi utenti, provenienti dallo stesso store.

GHAPP ACE 2.0
Tactical Advantage Group LLC

RHAPP ACE 2.0
Tactical Advantage Group LLC

ocScribe
Olympus Concepts LLC

CLDF ACLF-MELD calculator
Chronic Liver Disease Foundation Inc

marzo 18, 2025